Tag: Cdi treatment

While older antibiotics for *C. difficile* infections (CDI) are associated with high recurrence rates, fidaxomicin offers a significant improvement. This raises a key question for many patients and healthcare professionals: **How does fidaxomicin work against C. diff** so effectively?

According to a 2021 guideline update by the Infectious Diseases Society of America (IDSA), fidaxomicin is the preferred treatment for initial and recurrent *Clostridioides difficile* infection (CDI). This shifts the long-standing practice of using vancomycin first-line. The primary reason behind this recommendation is the significant reduction in recurrence rates observed with fidaxomicin compared to vancomycin. So, **why is fidaxomicin preferred over vancomycin?**